Novocure missed quarterly sales expectations Thursday as total U.S. patients actively using its cancer treatment declined for the first time ever — prompting NVCR stock to topple.
Novocure Stock Skids On Surprise Loss As Revenue Also Falls Short
2021-04-29T13:49:32-04:00April 29th, 2021|